LEGN
Legend Biotech Corporation NASDAQ Listed Jun 5, 2020$28.56
Mkt Cap $5.3B
52w Low $16.24
42.4% of range
52w High $45.30
50d MA $20.24
200d MA $26.84
P/E (TTM)
-14.7x
EV/EBITDA
-32.6x
P/B
4.3x
Debt/Equity
0.4x
ROE
—
P/FCF
-23.8x
RSI (14)
—
ATR (14)
—
Beta
0.08
50d MA
$20.24
200d MA
$26.84
Avg Volume
2.0M
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
2101 Cottontail Lane · Somerset, NJ 08873 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 10, 2026 | AMC | -0.17 | -0.08 | +52.9% | 19.56 | +0.5% | +3.6% | -6.0% | -1.6% | +1.9% | -2.9% | — |
| Nov 12, 2025 | AMC | -0.13 | -0.11 | +15.4% | 31.18 | -1.3% | -0.5% | -2.3% | -1.9% | -1.0% | -4.8% | — |
| Aug 11, 2025 | AMC | -0.22 | -0.34 | -54.5% | 36.24 | -0.3% | +2.1% | -0.2% | +2.1% | -0.6% | -0.1% | — |
| May 13, 2025 | AMC | -0.40 | -0.07 | +82.5% | 31.08 | +0.7% | -10.6% | -0.4% | +0.3% | +4.8% | +3.3% | — |
| Mar 11, 2025 | AMC | -0.39 | -0.15 | +61.5% | 37.19 | +1.9% | +2.8% | -0.5% | -2.2% | +2.0% | -0.2% | — |
| Aug 9, 2024 | AMC | -0.54 | -0.05 | +90.7% | 55.90 | +2.4% | +0.6% | +1.5% | -4.2% | +2.0% | +2.0% | — |
| May 13, 2024 | AMC | -0.29 | -0.16 | +44.8% | 42.97 | +0.7% | +3.3% | +3.1% | +1.3% | -2.6% | +0.6% | — |
| Mar 11, 2024 | AMC | -0.70 | -0.40 | +42.9% | 65.19 | -0.6% | -0.1% | +4.4% | -2.8% | -3.2% | +1.0% | — |
| Nov 20, 2023 | AMC | -0.56 | -0.17 | +69.6% | 60.50 | +0.0% | -5.4% | +5.0% | +0.6% | +1.8% | -2.6% | — |
| Aug 15, 2023 | AMC | -0.69 | -0.27 | +60.9% | 66.95 | +0.4% | +1.0% | -1.1% | -0.8% | +2.6% | +2.2% | — |
| May 18, 2023 | AMC | -0.56 | -0.40 | +28.6% | 68.94 | +4.6% | +1.1% | -1.1% | -3.5% | -0.8% | -4.2% | — |
| Mar 30, 2023 | AMC | -0.44 | -0.85 | -94.2% | 48.00 | -2.1% | +0.5% | -2.4% | -1.7% | +4.1% | +6.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.07 | $25.08 | +0.0% | +0.6% | +2.8% | -7.5% | -0.4% | -1.0% |
| Apr 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.69 | $18.92 | +1.2% | +9.8% | +2.7% | +0.4% | +18.4% | +0.6% |
| Mar 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $19.56 | $19.66 | +0.5% | +3.6% | -6.0% | -1.6% | +1.9% | -2.9% |
| Mar 11 | RBC Capital | Maintains | Outperform → Outperform | — | $19.56 | $19.66 | +0.5% | +3.6% | -6.0% | -1.6% | +1.9% | -2.9% |
| Feb 4 | Barclays | Maintains | Overweight → Overweight | — | $16.66 | $16.61 | -0.3% | -0.1% | +0.3% | +2.4% | +0.5% | +4.2% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.76 | $20.08 | -3.3% | -6.8% | -1.7% | -0.3% | -3.6% | -2.3% |
| Jan 22 | TD Cowen | Downgrade | Buy → Hold | — | $20.76 | $20.08 | -3.3% | -6.8% | -1.7% | -0.3% | -3.6% | -2.3% |
| Jan 20 | RBC Capital | Maintains | Outperform → Outperform | — | $22.14 | $21.70 | -2.0% | +5.8% | -11.4% | -6.8% | -1.7% | -0.3% |
| Dec 17 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $21.65 | $21.67 | +0.1% | -1.1% | -0.7% | +3.0% | +3.5% | +0.7% |
| Dec 12 | Morgan Stanley | Maintains | Overweight → Overweight | — | $23.01 | $22.91 | -0.4% | -3.0% | -1.4% | -1.6% | -1.1% | -0.7% |
| Dec 8 | UBS | Maintains | Buy → Buy | — | $28.13 | $27.84 | -1.0% | -7.1% | -8.6% | -2.2% | -1.5% | -3.0% |
| Nov 13 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $31.18 | $30.77 | -1.3% | -0.5% | -2.3% | -1.9% | -1.0% | -4.8% |
| Nov 13 | Barclays | Maintains | Overweight → Overweight | — | $31.18 | $30.77 | -1.3% | -0.5% | -2.3% | -1.9% | -1.0% | -4.8% |
| Nov 13 | RBC Capital | Maintains | Outperform → Outperform | — | $31.18 | $30.77 | -1.3% | -0.5% | -2.3% | -1.9% | -1.0% | -4.8% |
| Oct 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.36 | $31.80 | -1.7% | -1.2% | +3.0% | -0.2% | -2.3% | -1.4% |
| Oct 9 | JP Morgan | Maintains | Overweight → Overweight | — | $32.21 | $32.05 | -0.5% | +0.0% | -1.6% | +3.6% | +1.2% | +1.5% |
| Aug 25 | JP Morgan | Maintains | Overweight → Overweight | — | $35.56 | $35.72 | +0.4% | -2.7% | +1.4% | -1.0% | -1.0% | +1.0% |
| Aug 12 | RBC Capital | Maintains | Outperform → Outperform | — | $36.24 | $36.13 | -0.3% | +2.1% | -0.2% | +2.1% | -0.6% | -0.1% |
| Aug 12 | Morgan Stanley | Maintains | Overweight → Overweight | — | $36.24 | $36.13 | -0.3% | +2.1% | -0.2% | +2.1% | -0.6% | -0.1% |
| Jul 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.75 | $41.20 | +3.6% | +6.0% | -1.3% | +1.5% | +4.2% | +0.7% |
| Jul 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $39.46 | $39.53 | +0.2% | +0.6% | -1.9% | +1.2% | +0.4% | +0.4% |
| Jul 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $35.87 | $35.78 | -0.3% | +4.5% | +5.3% | +0.6% | -1.9% | +1.2% |
| Jul 2 | UBS | Maintains | Buy → Buy | — | $36.29 | $36.30 | +0.0% | -1.0% | -0.8% | +0.6% | +4.5% | +5.3% |
| May 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $31.08 | $31.30 | +0.7% | -10.6% | -0.4% | +0.3% | +4.8% | +3.3% |
| May 14 | Truist | Maintains | Buy → Buy | — | $31.08 | $31.30 | +0.7% | -10.6% | -0.4% | +0.3% | +4.8% | +3.3% |
| Apr 22 | RBC Capital | Maintains | Outperform → Outperform | — | $32.24 | $32.99 | +2.3% | +6.9% | -0.5% | -0.2% | +0.1% | +1.2% |
| Apr 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.74 | $33.39 | -1.0% | -0.8% | -2.0% | -1.7% | +6.9% | -0.5% |
| Apr 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.25 | $31.44 | +3.9% | +1.7% | +4.3% | -2.5% | +2.3% | +0.3% |
| Mar 17 | Morgan Stanley | Maintains | Overweight → Overweight | — | $37.20 | $37.41 | +0.6% | +2.0% | -0.2% | +0.5% | -0.9% | -2.0% |
| Mar 12 | Guggenheim | Maintains | Neutral → Neutral | — | $37.19 | $37.91 | +1.9% | +2.8% | -0.5% | -2.2% | +2.0% | -0.2% |
| Mar 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.19 | $37.91 | +1.9% | +2.8% | -0.5% | -2.2% | +2.0% | -0.2% |
| Jan 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.44 | $37.42 | -0.1% | +0.7% | -2.1% | -0.7% | -1.7% | +0.2% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.67 | $36.75 | +6.0% | +8.0% | +0.7% | -2.1% | -0.7% | -1.7% |
| Jan 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.66 | $33.41 | +2.3% | +6.2% | +8.0% | +0.7% | -2.1% | -0.7% |
| Dec 30 | Piper Sandler | Maintains | Overweight → Overweight | — | $32.49 | $32.42 | -0.2% | +0.9% | -0.7% | +6.7% | +3.0% | -3.0% |
| Dec 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.63 | $41.50 | -0.3% | -9.0% | -5.4% | -1.0% | -1.0% | -6.0% |
| Dec 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $41.54 | $42.68 | +2.7% | +0.2% | -9.0% | -5.4% | -1.0% | -1.0% |
| Dec 9 | RBC Capital | Maintains | Outperform → Outperform | — | $41.54 | $42.68 | +2.7% | +0.2% | -9.0% | -5.4% | -1.0% | -1.0% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.18 | $40.50 | +0.8% | -2.1% | +1.4% | -4.3% | -2.0% | +2.6% |
| Oct 29 | RBC Capital | Maintains | Outperform → Outperform | — | $45.30 | $45.35 | +0.1% | +0.4% | -2.6% | +1.7% | -1.5% | -1.7% |
| Oct 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $44.91 | $45.00 | +0.2% | -2.0% | -2.1% | -0.5% | +1.4% | +3.7% |
| Oct 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $47.79 | $48.92 | +2.4% | +2.7% | +1.0% | -3.1% | +1.6% | +2.9% |
| Sep 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $49.27 | $50.93 | +3.4% | -1.1% | -2.6% | +2.5% | -1.8% | +2.7% |
| Sep 27 | RBC Capital | Maintains | Outperform → Outperform | — | $46.85 | $47.32 | +1.0% | +5.2% | -1.1% | -2.6% | +2.5% | -1.8% |
| Aug 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $57.02 | $57.40 | +0.7% | -0.6% | +0.1% | +1.5% | -0.4% | +0.1% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $55.90 | $57.24 | +2.4% | +0.6% | +1.5% | -4.2% | +2.0% | +2.0% |
| Aug 12 | RBC Capital | Maintains | Outperform → Outperform | — | $55.90 | $57.24 | +2.4% | +0.6% | +1.5% | -4.2% | +2.0% | +2.0% |
| Aug 12 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $55.90 | $57.24 | +2.4% | +0.6% | +1.5% | -4.2% | +2.0% | +2.0% |
| Jul 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $55.00 | $54.97 | -0.1% | +5.9% | +0.9% | +0.3% | +1.6% | -0.4% |
| Jul 18 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $55.00 | $54.97 | -0.1% | +5.9% | +0.9% | +0.3% | +1.6% | -0.4% |
No insider trades available.
No recent filings available.
Data updated apr 26, 2026 11:19am
· Source: massive.com